Indaptus Therapeutics, Inc.
INDP
$0.2701
-$0.0589-17.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.52M | 8.11M | 8.57M | 8.91M | 8.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.00M | 15.37M | 15.37M | 16.48M | 15.87M |
| Operating Income | -16.00M | -15.37M | -15.37M | -16.48M | -15.87M |
| Income Before Tax | -15.75M | -15.02M | -14.89M | -15.75M | -14.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.75 | -15.02 | -14.89 | -15.75 | -14.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.75M | -15.02M | -14.89M | -15.75M | -14.98M |
| EBIT | -16.00M | -15.37M | -15.37M | -16.48M | -15.87M |
| EBITDA | -16.00M | -15.37M | -15.37M | -16.48M | -15.86M |
| EPS Basic | -1.49 | -1.62 | -1.72 | -1.86 | -1.78 |
| Normalized Basic EPS | -0.93 | -1.01 | -1.08 | -1.17 | -1.11 |
| EPS Diluted | -1.49 | -1.62 | -1.72 | -1.86 | -1.78 |
| Normalized Diluted EPS | -0.93 | -1.01 | -1.08 | -1.17 | -1.11 |
| Average Basic Shares Outstanding | 43.08M | 37.42M | 34.90M | 33.79M | 33.65M |
| Average Diluted Shares Outstanding | 43.08M | 37.42M | 34.90M | 33.79M | 33.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |